MW 264.32 Da, Purity >98%. Potent, selective VEGFR and PDGFR tyrosine kinases inhibitor (IC50 values are 0.8 and 19.4 μM respectively). Shows anti-angiogenic effects. Active in vivo.
5812-07-7
> 98%
Solid
264.32 Da
C17H16N2O
6450842
Synthetic
A BETA, A4 amyloid protein, A4_HUMAN, AAA, ABPP, AD1, AI413597, AICD-50, AICD-57, AICD-59, AID(50), AID(57), AID(59), ANP-A, ANPRA_HUMAN, APP, APPI, AW045860, Alpha-synuclein, Alpha-synuclein, isoform NACP140, Alzheimer disease amyloid protein, Amyloid beta (A4) precursor protein, Amyloid beta A4 protein, Amyloid beta protein, Amyloid intracellular domain 50, Amyloid intracellular domain 57, Amyloid intracellular domain 59, Amyloid precursor protein, Atrial natriuretic peptide A type receptor, Atrial natriuretic peptide receptor 1, Atrial natriuretic peptide receptor A, Atrial natriuretic peptide receptor type A, Atrionatriuretic peptide receptor A, Beta-APP40, Beta-APP42, Beta-amyloid precursor protein, C31, CTFgamma, CVAP, Cerebral vascular amyloid peptide, DDPAC, EC 2.7.10.1, FLJ31424, FLT, FRT, FTDP 17, Flt-1, Fms related tyrosine kinase 1, Fms related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor), Fms related tyrosine kinase 1 vascular endothelial growth factor/vascular permeability factor receptor, Fms-like tyrosine kinase 1, G protein beta1/gamma2 subunit interacting factor 1, GC-A, GUCY2A, Gamma-CTF(50), Gamma-CTF(57), Gamma-CTF(59), Guanylate cyclase, Guanylate cyclase A, MAPT, MAPTL, MGC105443, MGC110988, MGC127560, MGC134287, MGC138549, MGC156663, MGC64356, MSTD, MTBT1, MTBT2, Microtubule associated protein tau isoform 4, Microtubule-associated protein tau, Mtapt, NACP, NPC, NPC1_HUMAN, NPR-A, NPR1, Natriuretic Peptide Receptor A, Natriuretic peptide A type receptor, Natriuretic peptide receptor A/guanylate cyclase A, Neurofibrillary tangle protein, Niemann Pick C1 protein precursor, Niemann Pick disease, type C1, Niemann-Pick C1 protein, Non A4 component of amyloid, Non-A beta component of AD amyloid, Non-A-beta component of alzheimers disease amyloid , precursor of, Non-A4 component of amyloid precursor, Non-A4 component of amyloid, precursor of, OTTHUMP00000218549, OTTHUMP00000218551, OTTHUMP00000218552, OTTHUMP00000218553, OTTHUMP00000218554, PARK 1, PARK 4, PHF-tau, PN 2, PN-II, PPND, PPP1R103, Paired helical filament-tau, Parkinson disease (autosomal dominant, Lewy body) 4, Parkinson disease familial 1, PreA4, Protease nexin-II, Protein phosphatase 1, regulatory subunit 103, RNPTAU, S-APP-alpha, S-APP-beta, SNCA, SYN, SYUA_HUMAN, Snca synuclein, Snca synuclein, alpha (non A4 component of amyloid precursor), Soluble VEGF receptor 1 14, Soluble VEGFR1 variant 2, Soluble VEGFR1 variant 21, Synuclein alpha, Synuclein alpha 140, Synuclein, alpha (non A4 component of amyloid precursor), TAU_HUMAN, Tauopathy and respiratory failure, Tauopathy and respiratory failure, included, Tyrosine-protein kinase FRT, Tyrosine-protein kinase receptor FLT, VEGFR-1, VGFR1_HUMAN, Vascular endothelial growth factor receptor 1, Vascular endothelial growth factor vascular permeability factor receptor, Vascular permeability factor receptor, Vascular permeability factor receptor 1, alphaSYN, beta-amyloid peptide, pTau, peptidase nexin-II, sAPP
MW 264.32 Da, Purity >98%. Potent, selective VEGFR and PDGFR tyrosine kinases inhibitor (IC50 values are 0.8 and 19.4 μM respectively). Shows anti-angiogenic effects. Active in vivo.
5812-07-7
> 98%
Solid
264.32 Da
C17H16N2O
6450842
Synthetic
Soluble in DMSO to 75 mM.
3-(4-(Dimethylamino)benzylidene)-1,3-dihydro-2H-indol-2-one
Potent, selective VEGFR and PDGFR tyrosine kinases inhibitor (IC50 values are 0.8 and 19.4 μM respectively). Shows anti-angiogenic effects. Active in vivo.
CN(C)C1=CC=C(C=C1)C=C2C3=CC=CC=C3NC2=O
CN(C)C1=CC=C(C=C1)/C=C\2/C3=CC=CC=C3NC2=O
InChI=1S/C17H16N2O/c1-19(2)13-9-7-12(8-10-13)11-15-14-5-3-4-6-16(14)18-17(15)20/h3-11H,1-2H3,(H,18,20)/b15-11-
UAKWLVYMKBWHMX-PTNGSMBKSA-N
(3Z)-3-[[4-(dimethylamino)phenyl]methylidene]-1H-indol-2-one
Ambient - Can Ship with Ice
-20°C
-20°C
Store under desiccating conditions, The product can be stored for up to 12 months
This supplementary information is collated from multiple sources and compiled automatically.
Amyloid Precursor Protein (APP) Tau and Alpha-synuclein are proteins with significant roles in neurological diseases. APP is a membrane protein that is cleaved to create amyloid-beta linked with Alzheimer's disease. Its mass is around 100-140 kDa depending on isoform. APP is mainly expressed in the brain in neurons. Tau protein another key player helps stabilize microtubules and has a mass of about 50-65 kDa. It is found widely in the central nervous system. Alpha-synuclein also prevalent in the brain especially in presynaptic terminals is involved in numerous synaptic functions. The VEGF Receptor 1 also known as FLT1 mainly modulates angiogenesis expressed in vascular endothelial cells. The NPR-A or guanylyl cyclase-A receptor binds natriuretic peptides and facilitates vascular and renal homeostasis. Niemann-Pick C1 protein (NPC1) is found in late endosomes and lysosomes and it regulates cholesterol trafficking in cells.
APP processes give rise to amyloid-beta impacting neural network activities and contributing to plaque formation in Alzheimer’s disease. Tau protein often binding with tubulin assists in microtubule assembly but also shows aggregation in neurodegenerative conditions. Alpha-synuclein's role in synaptic vesicle regulation hints at neurotransmitter release involvement. VEGF Receptor 1 supports blood vessel growth and maintenance forming complexes with other kinases linked receptors like PDGF receptors. NPR-A mediates natriuresis and blood pressure regulation while cooperatively functioning with complex signaling pathways. NPC1 maintains cellular lipid sorting and cholesterol homeostasis contributing to the prevention of lipid build-up in lysosomes.
APP and its generated amyloid-beta partake in synaptic functions and APP processing pathways interacting with proteins like presenilin and BACE1 in Alzheimer's disease pathways. Tau participates in the MAPK/ERK pathway important for neuronal health where hyperphosphorylation affects its role in cell stability. Alpha-synuclein is integral in dopaminergic pathways often associating with PARK7 in Parkinson's disease. VEGF Receptor 1 is actively involved in angiogenesis pathways together with kinases linked receptors influencing cellular responses to PDGFR activators. NPR-A regulates the cGMP pathway impacting natriuretic peptide signaling. NPC1 plays a role in lipid transport pathways engaging with proteins regulating cholesterol storage and efflux.
Beta-amyloid and Tau are strongly linked to Alzheimer's disease. These proteins through abnormal aggregation contribute significantly to neurodegeneration and cognitive decline. Alpha-synuclein through its misfolded forms remains a central figure in Parkinson's disease pathogenesis promoting dopaminergic neuron loss. VEGF Receptor 1 through endothelial dysfunction associates with cancer progression due to its influence on tumor angiogenesis. NPR-A dysfunctions connect with cardiovascular diseases through disrupted natriuretic peptide signaling. Niemann-Pick C1 malfunction results in Niemann-Pick disease type C where it causes severe lipid accumulation in lysosomes showcasing connections to cholesterol management disorders.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2D chemical structure image of ab141577, SU4312, VEGFR and PDGFR receptor tyrosine kinase inhibitor
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com